When a drug earns regulatory approval, it typically does so for one specific condition, one carefully defined population, and one primary benefit that its developers spent years proving. Finerenone, sold under the brand name Kerendia and developed by Bayer, followed that path when the United States Food and Drug Administration approved it in 2021 to slow the progression of chronic kidney disease in adults with type 2 diabetes. That approval was significant enough on its own, because diabetic kidney disease is the leading cause of end-stage kidney failure in the world, affecting hundreds of millions of people and carrying a mortality rate that rivals many cancers. But in the years since that approval, something unexpected has been happening in research laboratories and clinical trial centers across the globe. Study after study has been finding that finerenone does considerably more than its original label suggests, and the cumulative evidence is now reshaping how cardiologists, nephrologists, and diabetes specialists think about treating their most vulnerable patients.
To appreciate why these findings matter so much, it helps to understand the specific problem finerenone was designed to solve. The kidneys are extraordinary organs, filtering roughly 180 liters of blood every single day and maintaining a chemical balance that keeps the rest of the body alive. In people with type 2 diabetes, chronically high blood sugar damages the tiny filtering units inside the kidneys called glomeruli, triggering a cascade of inflammation and scarring that progressively destroys kidney function. Doctors measure this deterioration partly through a protein called albumin, which in healthy kidneys stays in the blood but leaks into urine when the filters are damaged, and partly through a calculation called the estimated glomerular filtration rate, or eGFR, which tells them how efficiently the kidneys are cleaning the blood. Once eGFR begins falling and albumin starts appearing in the urine, the clock is effectively ticking toward dialysis or a kidney transplant unless something intervenes. Approximately 537 million people worldwide live with type 2 diabetes today, and a substantial portion of them will develop kidney complications, meaning the scale of the problem is staggering.
The FIDELIO-DKD trial enrolled 5,674 patients with type 2 diabetes and moderate-to-severe chronic kidney disease (CKD stages 3 to 4, eGFR 25 to <75 mL/min/1.73m²) across multiple countries. Patients received finerenone or placebo on top of the maximum dose of standard renin-angiotensin system blocking therapy they could tolerate.
Over a median follow-up of 2.6 years, finerenone reduced the primary kidney composite outcome, kidney failure, a sustained 40% or greater decline in eGFR, or death from kidney causes, by a statistically significant margin. The drug also cut the secondary cardiovascular composite endpoint, which included cardiovascular death, non-fatal heart attack, non-fatal stroke, and hospitalization for heart failure.
What made finerenone different from the drugs that came before it is rooted in its mechanism of action. The kidneys and the heart share a hormonal signaling system called the renin-angiotensin-aldosterone system, or RAAS, and when this system becomes overactive, as it does in chronic kidney disease and heart failure, it triggers excessive stimulation of a receptor protein called the mineralocorticoid receptor. This receptor, when persistently activated, drives inflammation and fibrosis, essentially causing organs to scar themselves from the inside. Older drugs called steroidal mineralocorticoid receptor antagonists, including spironolactone and eplerenone, have been used for decades to block this process, but they come with two significant problems: they cause hormonal side effects because they are not selective enough, and they raise blood potassium to dangerous levels frequently enough that many patients with kidney disease simply cannot take them safely. Finerenone is a non-steroidal mineralocorticoid receptor antagonist that binds the receptor with far greater selectivity, blocking the fibrosis and inflammation pathways without the hormonal side effects and with a substantially more manageable potassium risk profile. That biological precision, it turns out, is where the breadth of its benefits begins.
"Finerenone reduces the risk of clinical cardiovascular outcomes and kidney disease progression across a broad range of patients with chronic kidney disease and type 2 diabetes."
FIDELITY Pooled Analysis — European Heart Journal, 2022The trial that first put finerenone on the map was FIDELIO-DKD, a large phase III study that enrolled patients with more advanced kidney disease and asked a straightforward question: compared to a placebo added onto the best existing standard of care, does finerenone protect the kidneys? The answer was a clear yes. The pooled analysis that followed, called FIDELITY, which combined data from both FIDELIO-DKD and its companion trial FIGARO-DKD to produce a dataset of over 13,000 patients, gave researchers the statistical power to paint an even fuller picture. Across that combined population, finerenone reduced the hazard of the composite kidney outcome by 23% compared to placebo, with a hazard ratio of 0.77. More specifically, it reduced the risk of progressing to end-stage kidney disease, the point where a patient requires dialysis or a transplant, by 20%, with a hazard ratio of 0.80. These are not trivial numbers. For a disease that currently has no cure, slowing the march toward dialysis by a fifth represents a genuine and meaningful improvement in quality of life for millions of people.
FIGARO-DKD, the companion trial to FIDELIO-DKD, enrolled a different slice of the same disease, patients with earlier-stage kidney disease and primarily cardiovascular risk, and its findings were where the story began to expand beyond the kidneys in earnest. Published in the New England Journal of Medicine in 2021, FIGARO-DKD demonstrated that finerenone significantly reduced the primary cardiovascular composite outcome, which included cardiovascular death, non-fatal heart attack, non-fatal stroke, and hospitalization for heart failure. But the deeper analysis of FIGARO-DKD data, published in Circulation, zeroed in on something that caught many cardiologists off guard: the drug's specific impact on heart failure. New-onset heart failure, meaning patients who had no prior history of the condition developing it for the first time during the study, was reduced by a remarkable 32% with finerenone compared to placebo, with a hazard ratio of 0.68 and a p-value of 0.016. Hospitalization for heart failure fell by 29%. The total rate of heart failure hospitalizations, counting both first and recurrent events, dropped by 30%. These were not secondary footnotes to the kidney story, they were a headline of their own.
New-onset heart failure: Reduced from 2.8% (placebo) to 1.9% (finerenone), a 32% relative risk reduction (HR 0.68; 95% CI 0.50 to 0.93; p = 0.016).
First hospitalization for heart failure: 29% lower risk with finerenone (HR 0.71; 95% CI 0.56 to 0.90; p = 0.004).
Total heart failure hospitalizations (first and recurrent): 30% lower rate with finerenone (rate ratio 0.70; 95% CI 0.52 to 0.94).
These benefits were consistent regardless of whether patients had a prior history of heart failure at the start of the trial.
To understand why a kidney drug would reduce heart failure so substantially, it helps to think about how these two conditions are connected. In most people's minds, heart disease and kidney disease are separate problems treated by separate specialists in separate clinics. In reality, they are two expressions of the same underlying biological dysfunction. When the mineralocorticoid receptor is chronically overstimulated in the kidney, the same process is simultaneously occurring in the heart muscle, causing progressive fibrosis — essentially a slow hardening and stiffening, that reduces the heart's ability to fill and pump properly. This is particularly relevant to a form of heart failure called heart failure with preserved or mildly reduced ejection fraction, abbreviated as HFpEF or HFmrEF, which accounts for roughly half of all heart failure cases and has historically been very difficult to treat because the heart's pumping strength appears relatively normal even while its filling function deteriorates. Finerenone's precise blockade of the mineralocorticoid receptor addresses the fibrosis pathway common to both conditions simultaneously, which is why its cardiovascular benefits appeared even in a trial primarily designed to test kidney outcomes.
In August 2024, at the European Society of Cardiology Congress in London, researchers presented the full results of the FINEARTS-HF trial , a phase III study of 6,001 patients with symptomatic heart failure and a left ventricular ejection fraction of 40% or greater, which is the preserved-to-mildly-reduced range that has long lacked proven treatments.
Finerenone became the first mineralocorticoid receptor antagonist ever to demonstrate definitive cardiovascular benefit in a phase III trial for this form of heart failure. The trial recorded 1,083 primary outcome events in 624 patients in the finerenone group versus 1,283 events in 719 patients in the placebo group, a rate ratio of 0.84, representing a 16% reduction in the composite of cardiovascular death and total worsening heart failure events.
The reduction was primarily driven by fewer worsening heart failure events, with a hazard ratio of 0.790 (p < 0.001) across the pooled meta-analysis. This result carried particular weight because HFpEF and HFmrEF together affect an estimated 32 million people worldwide, and until FINEARTS-HF, no drug had convincingly moved the needle on hard outcomes in this population.
The FINEARTS-HF result opened another important door. Before this trial, finerenone had only been studied in patients who also had type 2 diabetes and kidney disease, a specific combination. FINEARTS-HF included patients with heart failure regardless of whether they had diabetes or kidney disease in the same way as the earlier trials, which suggested that the drug's anti-fibrotic and anti-inflammatory benefits operate through a mechanism broad enough to help patients across a wider spectrum of disease. This matters enormously because heart failure with preserved ejection fraction is one of the fastest-growing cardiovascular conditions in the world, driven partly by aging populations and partly by rising rates of obesity, diabetes, and hypertension. An effective treatment for this form of heart failure has been one of cardiology's most-wanted discoveries for decades.
Then came the FINE-HEART analysis, published in Nature Medicine in October 2024, which may be the most comprehensive single piece of evidence assembled on finerenone so far. The researchers took the individual patient data from all three major trials, FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF, and pooled them into a single prespecified analysis covering 18,991 participants with a mean age of 67 years and a median follow-up of 2.9 years. The scale of that dataset made it possible to detect effects that individual trials could only gesture toward. The headline finding was on all-cause mortality: deaths from any cause occurred in 11.0% of patients on finerenone versus 12.0% on placebo, a statistically significant 9% reduction in the hazard of dying from anything (hazard ratio 0.91; 95% CI 0.84 to 0.99; p = 0.027). Cardiovascular death also showed a consistent directional benefit across all three trials, with a combined hazard ratio of 0.89, although that specific result narrowly missed conventional statistical significance thresholds in the pooled analysis.
Total patients across 3 trials: 18,991 (mean age 67 ± 10 years; 35% women)
All-cause mortality: 11.0% (finerenone) vs 12.0% (placebo) , HR 0.91; 95% CI 0.84–0.99; p = 0.027
Cardiovascular death: 4.4% vs 5.0%, HR 0.89; 95% CI 0.78–1.01 (consistent trend across all three trials)
Kidney composite outcome (FIDELITY): Finerenone reduced the hazard by 23% (HR 0.77; 95% CI 0.67–0.88)
End-stage kidney disease: Risk reduced by 20% (HR 0.80; 95% CI 0.64–0.99)
A mortality reduction of 9% across nearly 19,000 patients, on top of already optimized standard care, is a finding that demands attention. To put it in human terms: if finerenone were widely prescribed to the eligible population of patients with chronic kidney disease and type 2 diabetes globally, a population estimated in the tens of millions, even a modest absolute mortality reduction translates into hundreds of thousands of lives extended. Researchers at the European Heart Journal noted in their FIDELITY analysis that finerenone's cardiorenal benefits appeared to operate largely independently of the blood pressure lowering it produces, with only modest reductions in blood pressure observed in the trials. This suggests the drug is doing something more fundamental through its anti-fibrotic and anti-inflammatory pathways rather than simply acting as a better blood pressure pill, which makes the breadth of its effects more biologically coherent and the durability of those effects more likely.
The meta-analysis published in Frontiers in Endocrinology in December 2024, drawing on four randomized controlled trials involving 13,943 participants, added further texture to the picture. It confirmed that finerenone significantly decreased the urine albumin-to-creatinine ratio, that key marker of kidney leakage, while also reducing the risk of a 40% or greater decline in kidney filtration rate. The analysis found no increase in the overall rate of adverse events (risk ratio 1.00) and no elevated cancer risk (risk ratio 0.99) compared to placebo, reinforcing finerenone's favorable safety profile. The one consistent caution throughout all the literature is the risk of elevated blood potassium, technically called hyperkalemia, which the drug raises by blocking aldosterone's action. In the stage 4 CKD subgroup analyzed in FIDELITY, hyperkalemia occurred in 26% of finerenone patients versus 13% on placebo. However, the rate of hyperkalemia severe enough to require permanently stopping the drug was low, just 3% in the most vulnerable patients, and regular blood potassium monitoring at prescription and follow-up visits is sufficient to manage this risk safely for most patients.
"The pooled FIDELITY analysis, encompassing more than 13,000 participants across the CKD spectrum, provided comprehensive evidence supporting finerenone's efficacy in reducing both renal and cardiovascular mortality."
Clinical Trial Analysis Summary — Kidney International, 2025One of the more clinically exciting angles in current research involves combining finerenone with another class of drugs called SGLT2 inhibitors, such as dapagliflozin and empagliflozin, which also have proven kidney and heart-protective effects. The CONFIDENCE trial was designed specifically to test whether finerenone and an SGLT2 inhibitor taken together produce additive benefits beyond what either drug achieves alone in patients with type 2 diabetes and chronic kidney disease. Early results from this phase II study have been encouraging, suggesting the combination further reduces albuminuria beyond what either drug achieves individually, and larger outcomes data from ongoing programs are anticipated to clarify whether the combination should become a new standard of care. The thinking behind the combination is elegant: SGLT2 inhibitors and finerenone protect the kidneys and heart through complementary and largely non-overlapping pathways, so stacking them could deliver the kind of double protection that patients with both diabetes and kidney disease urgently need. Intriguingly, the FIDELITY analysis found that the roughly 7% of patients already taking an SGLT2 inhibitor at the start of the trials showed consistent benefits from adding finerenone on top, lending real-world plausibility to the combination strategy.
Beyond the combination therapy angle, researchers are also exploring whether finerenone's benefits extend to patients with chronic kidney disease who do not have diabetes at all. An estimated 37 million American adults have chronic kidney disease, and a substantial proportion reached that diagnosis through causes other than diabetes
, including high blood pressure, autoimmune conditions, and inherited diseases. The mineralocorticoid receptor overactivation that finerenone targets is present across many of these non-diabetic forms of CKD as well, making the drug biologically plausible in a broader population. The FIND-CKD trial program is specifically designed to test this hypothesis in non-diabetic patients, and results from that program will be closely watched by the nephrology community over the coming years. If finerenone proves effective in non-diabetic CKD, its potential patient population would roughly double.
For a patient sitting across from a doctor today and wondering what all this research means practically, the picture is cleaner than the scientific detail might suggest. Finerenone is currently approved for chronic kidney disease in type 2 diabetes. It comes in two doses, 10 mg and 20 mg, with the starting dose determined by the patient's kidney function and blood potassium levels, and the dose typically adjusted upward after four weeks if potassium remains in a safe range. It is taken once daily, with or without food, and does not require the dietary restrictions or frequent dose adjustments that older potassium-sparing drugs demanded. The 2022 KDIGO guidelines, the international gold standard for kidney disease management, now recommend finerenone for patients with type 2 diabetes and CKD who are already on maximum tolerated doses of ACE inhibitors or ARBs, precisely because of the clinical trial evidence. The American Diabetes Association's 2024 Standards of Care similarly include finerenone as a recommended therapeutic option for this population. The drug is therefore not experimental or fringe , it has already earned a place in mainstream clinical guidelines and will likely expand its footprint as new trial results arrive.
Who it is approved for: Adults with type 2 diabetes and chronic kidney disease (with reduced eGFR and elevated urinary albumin) who are already on maximum tolerated doses of ACE inhibitors or ARBs.
How it is taken: Once daily, 10 mg or 20 mg depending on baseline kidney function, adjusted after 4 weeks of monitoring.
Main risk to monitor: Blood potassium elevation (hyperkalemia). Regular potassium and kidney function tests are required, especially in the first weeks of treatment.
Who should not take it: Patients with severely reduced kidney function (eGFR below 25), those already taking potassium supplements or potassium-raising drugs without monitoring, and patients with adrenal insufficiency.
Current guidelines supporting use: KDIGO 2022 Clinical Practice Guidelines, ADA Standards of Care 2024.
The broader story that finerenone is telling medicine is one that researchers have been trying to articulate for years: that the heart, the kidneys, and metabolic disease like type 2 diabetes are not three separate problems but one interconnected syndrome. Cardiologists have started calling this cardiovascular-kidney-metabolic syndrome, and the recognition that it needs to be treated as a unified biological problem rather than a collection of separate organ failures is reshaping clinical practice. Finerenone's journey from kidney drug to potential heart failure breakthrough to all-cause mortality reducer illustrates this perfectly. It was developed to protect one organ, and the science keeps finding that protecting one organ, when done through the right mechanism, ends up protecting the whole patient.
The real-world observation program called FINE-REAL, currently enrolling approximately 5,500 adults with chronic kidney disease and type 2 diabetes from 22 countries, will provide the kind of broad, diverse population data that randomized trials by their very design cannot always capture. Expected to complete enrollment by September 2027, it will tell researchers how finerenone performs across different ethnicities, dietary habits, healthcare systems, and levels of baseline disease control, the messy real world rather than the carefully controlled trial environment. The FIVE-STAR study is simultaneously exploring finerenone's effects on vascular stiffness and cardiorenal biomarkers, probing the biological mechanisms behind the outcomes benefits in finer detail. Together, this pipeline of evidence suggests that finerenone's story, far from being complete, is still in a relatively early chapter. The drug approved four years ago to slow one disease is now being studied as a potential pillar in preventing cardiovascular death, reducing kidney failure, and cutting overall mortality across a patient population that numbers in the tens of millions globally. Not many drugs earn that kind of second act, and the ones that do tend to define a generation of medical care.
Medical Disclaimer
The information presented in this article is intended for general educational and informational purposes only. It is based on published clinical research and peer-reviewed medical literature available at the time of writing, and is designed to help readers understand ongoing scientific developments in the field of kidney and cardiovascular medicine.
This article does not constitute medical advice, diagnosis, or treatment recommendations. Finerenone is a prescription medication and must only be used under the direct supervision of a licensed and qualified healthcare professional. The dosing, eligibility criteria, monitoring requirements, and suitability of finerenone vary significantly between individuals based on their specific medical history, kidney function, potassium levels, concurrent medications, and other clinical factors.
Do not start, stop, or alter any medication , including finerenone or any other drug mentioned in this article , based solely on what you have read here. Always consult your physician, nephrologist, cardiologist, or qualified healthcare provider before making any changes to your treatment plan.
WorldAtNet makes no warranties, express or implied, regarding the accuracy, completeness, or current applicability of the clinical data summarized in this article. Medical research evolves rapidly and treatment guidelines are subject to change. Readers are encouraged to consult the original published studies and speak with their healthcare team for the most up-to-date guidance.
0 Comments